2 results match your criteria: "China. fang.hao@zs-hospital.sh.cn.[Affiliation]"
Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial.
BMC Pharmacol Toxicol
June 2023
Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Background: The rapid worldwide spread of COVID-19 has caused a global health challenge with high mortality of severe or critically ill patients with COVID-19. To date, there is no specific efficient therapeutics for severe or critically ill patients with COVID-19. It has been reported that androgen is related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
View Article and Find Full Text PDFTherapeutic values of engineered immune cells: a precision-guided weapon.
Cell Biol Toxicol
April 2023
Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China.